trial
as of 2026-07-01The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCTId NCT00816907
at a glance
Phase 4 · Completed
Enrollment 146 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Primary completion 2010-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
146 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-01
Primary completion
2010-02
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Sponsors
National Institute of Mental Health (NIMH)Lead Sponsor
Investigators
3
L. Fredrik Jarskog, MDPrincipal Investigator
Jeffrey A. Lieberman, MDPrincipal Investigator
T. Scott Stroup, MD, MPHPrincipal Investigator
Sites
16 total
Palo Alto, United StatesBoca Raton, United StatesIowa City, United StatesWichita, United StatesGlen Burnie, United StatesBoston, United StatesWorcester, United StatesMinneapolis, United StatesAlbuquerque, United StatesNew York, United StatesRochester, United StatesCincinnati, United States
Facts & assertions
4 sourced
Enrollment
146
Phase
PHASE4
Primary Completion Date
2010-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator